SG11202112726SA - Stable formulations of recombinant proteins - Google Patents
Stable formulations of recombinant proteinsInfo
- Publication number
- SG11202112726SA SG11202112726SA SG11202112726SA SG11202112726SA SG11202112726SA SG 11202112726S A SG11202112726S A SG 11202112726SA SG 11202112726S A SG11202112726S A SG 11202112726SA SG 11202112726S A SG11202112726S A SG 11202112726SA SG 11202112726S A SG11202112726S A SG 11202112726SA
- Authority
- SG
- Singapore
- Prior art keywords
- recombinant proteins
- stable formulations
- formulations
- stable
- recombinant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921027358 | 2019-07-09 | ||
| PCT/IB2020/056361 WO2021005500A1 (en) | 2019-07-09 | 2020-07-07 | Stable formulations of recombinant proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112726SA true SG11202112726SA (en) | 2021-12-30 |
Family
ID=72046948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112726SA SG11202112726SA (en) | 2019-07-09 | 2020-07-07 | Stable formulations of recombinant proteins |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220339241A1 (en) |
| EP (1) | EP3996680A1 (en) |
| JP (1) | JP2022539494A (en) |
| KR (1) | KR20220034053A (en) |
| CN (1) | CN114126584A (en) |
| AU (1) | AU2020311050A1 (en) |
| BR (1) | BR112021023265A2 (en) |
| CA (1) | CA3140609A1 (en) |
| MX (1) | MX2021015426A (en) |
| SG (1) | SG11202112726SA (en) |
| WO (1) | WO2021005500A1 (en) |
| ZA (1) | ZA202109011B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021005416A (en) * | 2018-11-19 | 2021-07-06 | Unichem Lab Ltd | Combination of chemotherapy with recombinant s. rolfsii lectin. |
| KR20240040820A (en) | 2021-07-08 | 2024-03-28 | 유니켐 레버러토리스 리미티드 | Recombinant proteins, compositions and methods for stabilizing the same |
| CA3227834A1 (en) | 2021-08-30 | 2023-03-09 | Dhananjay Sathe | Protein compositions for the treatment of inflammatory diseases |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011573A (en) | 2001-07-23 | 2007-08-08 | 纳蒂芒公司 | Production of high molecular mass lectins |
| WO2003018617A1 (en) | 2001-08-31 | 2003-03-06 | Fuso Pharmaceutical Industries, Ltd. | Method of purifying human mannose binding lectin, human mannose binding lectin compositions and medicinal use of human mannose binding lectin |
| NZ535600A (en) | 2002-04-24 | 2008-03-28 | Queensland Inst Med Res | MASP-depleted MBL compositions are superior at activating the complement cascade when compared with MBL purified in complex with its associated MASPs |
| JP4852703B2 (en) | 2004-08-27 | 2012-01-11 | 国立大学法人 新潟大学 | Brain tumor detection method and brain tumor detection substance used therefor |
| CN101485880A (en) | 2008-01-15 | 2009-07-22 | 上海新生源医药研究有限公司 | Pharmaceutical composition for treating immunodeficiency symptoms |
| LT3418296T (en) | 2009-02-18 | 2024-10-10 | Unichem Laboratories Limited | Cancer cell binding recombinant lectins with antitumor activity and method of preparation |
| WO2014203261A2 (en) | 2010-02-02 | 2014-12-24 | Unichem Laboratories Ltd. | Recombinant lectin and method of preparing thereof |
| EP2508195A1 (en) | 2011-04-06 | 2012-10-10 | Cytavis BioPharma GmbH | Medicine containing recombinant mistellectins for treating malignant melanoma |
| SG11201500632VA (en) | 2012-08-14 | 2015-02-27 | Univ Nanyang Tech | Anti-viral methods and the use of an anti-viral agent |
| WO2016178996A1 (en) * | 2015-05-01 | 2016-11-10 | The Regents Of The University Of California | Glycan-dependent immunotherapeutic molecules |
| RU2644332C1 (en) | 2016-12-30 | 2018-02-08 | Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") | Method for obtaining a vegetable ml1 lecture from a missile white and a pharmaceutical composition on its basis (variants) |
| SG11202101391WA (en) | 2018-08-31 | 2021-03-30 | Unichem Lab Ltd | Recombinant lectin variants |
| MX2021005416A (en) * | 2018-11-19 | 2021-07-06 | Unichem Lab Ltd | Combination of chemotherapy with recombinant s. rolfsii lectin. |
-
2020
- 2020-07-07 EP EP20754359.6A patent/EP3996680A1/en active Pending
- 2020-07-07 AU AU2020311050A patent/AU2020311050A1/en active Pending
- 2020-07-07 WO PCT/IB2020/056361 patent/WO2021005500A1/en unknown
- 2020-07-07 CN CN202080049225.XA patent/CN114126584A/en active Pending
- 2020-07-07 MX MX2021015426A patent/MX2021015426A/en unknown
- 2020-07-07 JP JP2021570936A patent/JP2022539494A/en active Pending
- 2020-07-07 US US17/623,748 patent/US20220339241A1/en active Pending
- 2020-07-07 KR KR1020217042194A patent/KR20220034053A/en unknown
- 2020-07-07 CA CA3140609A patent/CA3140609A1/en active Pending
- 2020-07-07 BR BR112021023265A patent/BR112021023265A2/en unknown
- 2020-07-07 SG SG11202112726SA patent/SG11202112726SA/en unknown
-
2021
- 2021-11-12 ZA ZA2021/09011A patent/ZA202109011B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022539494A (en) | 2022-09-12 |
| US20220339241A1 (en) | 2022-10-27 |
| EP3996680A1 (en) | 2022-05-18 |
| AU2020311050A1 (en) | 2021-12-23 |
| BR112021023265A2 (en) | 2022-03-08 |
| ZA202109011B (en) | 2022-07-27 |
| MX2021015426A (en) | 2022-01-24 |
| CA3140609A1 (en) | 2021-01-14 |
| CN114126584A (en) | 2022-03-01 |
| WO2021005500A1 (en) | 2021-01-14 |
| KR20220034053A (en) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202109011B (en) | Stable formulations of recombinant proteins | |
| SG11202109277WA (en) | Stable protein formulations | |
| GB2596998B (en) | Topical formulations of recombinant collagens | |
| IL286745A (en) | Continuous production of recombinant proteins | |
| ZA202100859B (en) | Recombinant protein variants | |
| EP3592800A4 (en) | Compositions and methods for producing high secreted yields of recombinant proteins | |
| IL290137A (en) | Application of polypeptide or derivative thereof | |
| ZA202006264B (en) | Stable formulations of therapeutic antibody | |
| EP3592762A4 (en) | Compositions and methods for producing high secreted yields of recombinant proteins | |
| ZA202007491B (en) | Stable fusion protein formulation | |
| IL283286A (en) | Pharmaceutical formulations of cyclosporine analogs | |
| IL291618A (en) | Heterodimeric proteins | |
| EP4057941A4 (en) | Stable formulations of silk-derived protein | |
| IL279782A (en) | Methods of producing recombinant proteins | |
| EP3807306A4 (en) | Leader sequence for higher expression of recombinant proteins | |
| EP3663313A4 (en) | N-terminal recombinant protein of ccr4 and usage thereof | |
| IL291127A (en) | N-terminal extension sequence for expression of recombinant therapeutic peptides | |
| EP3829625A4 (en) | Formulations for improved stability of recombinant human parathyroid hormone | |
| IL289219A (en) | Composition and methods for stabilizing liquid protein formulations | |
| IL279707A (en) | Pharmaceutical composition comprising polypeptide | |
| EP3679050A4 (en) | Methods and compositions for improved expression of recombinant proteins | |
| IL312467A (en) | Administration of c5-binding proteins | |
| PL3897213T3 (en) | Protein compositions with high isoelectric proteins | |
| GB202110607D0 (en) | New uses of proteins | |
| PL426662A1 (en) | Composition for intravitreal administration of therapeutic protein |